Evidence map›Paper›PMID 40087624›Full record

ArticleBMC cancer2025

Establishment and characterization of CHC-X1: the third human combined hepatocellular-cholangiocarcinoma cell line.

Huan Tang, Changpeng Chai, Xin Miao, Yuanhui Su, Cheng Yu, Jianfeng Yi, Zhengfeng Wang, Hui Zhang, Zhenjie Zhao, Linpei Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Huan Tang *The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
Changpeng Chai *The Fourth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, 730000, China.
Xin Miao *Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, 310006, China.
Yuanhui SuThe Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
Cheng YuThe Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
Jianfeng YiThe First Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
Zhengfeng WangThe Fourth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, 730000, China.
Hui ZhangThe Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
Zhenjie ZhaoThe Fourth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, 730000, China.
Linpei WangDepartment of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China. wlp@fjmu.edu.cn.
Wence ZhouThe Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China. zhouwc129@163.com.
Hao XuThe Fourth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, 730000, China. amoyxu@126.com.

Funding

Chengguan District Science and Technology Plan 2023SHFZ0018Lanzhou Science and Technology Plan Project 2023-2-38National Natural Science Foundation of China 82260555National Natural Science Foundation of China 82360510Natural Science Foundation of Gansu Province 23JRRA0929Natural Science Foundation of Gansu Province 23JRRA1601The Fund of The First Hospital of Lanzhou University ldyyyn2022-12
6 · The paper itself

Abstract

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) represents an uncommon variant of primary liver cancer. In recent years, its incidence rate has increased. Thus, it is essential to perform comprehensive investigations into cHCC-CCA to develop suitable treatment strategies. So far, only two cell lines (CLs) of this cancer type have been reported. More cHCC-CCA CLs need to be established for research purposes. In this investigation, we developed a stable cHCC-CCA CL, named CHC-X1. STR analysis confirmed that CHC-X1 is a new human cHCC-CCA CL. CHC-X1 is a complex karyotype. Its population doubling time is 50.72 h. Under suspended conditions, CHC-X1 can form tumor spheres and organoids in Matrigel. These cells exhibit sensitivity to paclitaxel while demonstrating resistance against oxaliplatin, gemcitabine, and 5-FU. After inoculation into NXG mice, CHC-X1 can quickly form subcutaneous transplant tumors, exhibiting a tumor establishment rate of 67%. Immunohistochemical staining showed that CHC-X1 is a tumor CL with both liver cell differentiation and bile duct cell differentiation characteristics. It may function as a useful model for identifying the origins of cHCC-CCA and the advancement of potential treatments.

Indexed as

Bile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsAnimalsCell DifferentiationCell Line, TumorHumansMiceXenograft Model Antitumor AssaysCell linesCombined hepatocellular-cholangiocarcinomaDrug resistanceDrug sensitivityTransplanted tumor

Identifiers

PMID40087624
PMCPMC11908078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.